Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T-Reference-Cited by-同舟云学术

Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T

Published:2022-04-18 Issue:6 Volume:23 Page:904-919
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Wiedmeier-Nutor Julia^ORCID,Leis Jose

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11864-022-00953-5.pdf

Reference60 articles.

1. National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic lymphoma (version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed 06/04/2021.

2. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 6:e366–74. https://doi.org/10.1016/S2352-3026(19)30085-7.

3. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278–91. https://doi.org/10.1016/S0140-6736(20)30262-2.

4. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghiaet P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373.25:2425–2437.

5. •• Burger JA, Barr PM, Robak TOC, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787–98. https://doi.org/10.1038/s41375-019-0602-x Randomized study showing high-risk CLL patients (TP53, IGHV mutation, etc.) had improved benefit with ibrutinib when compared to chlorambucil.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11

2. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies;Stem Cell Research & Therapy;2024-08-13

3. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs;Cancers;2024-07-31

4. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

5. Signaling pathways governing the behaviors of leukemia stem cells;Genes & Diseases;2024-03